RxDoctor Payments Data

Gary Silverman, DO

Rheumatology · Scottsdale, AZNPI 1154476539

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $603 of the $1,003 with a category attached, or 60.1%. 11 manufacturers reported payments, led by GSK at 43.8% of the total. 2025 is the largest year on record at $515, 2.7 times the $194 reported in 2019. That places this record below the midpoint for rheumatology clinicians in AZ, where the typical reported total is $3,203.

$1,003in general payments, 2019–2025

Across 29 payments — averaging $34.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$439
  • AbbVie$208
  • Lilly USA, LLC$115
  • Mallinckrodt Hospital Products Inc.$45
  • Johnson & Johnson$38
  • AstraZeneca$37
  • plus $120 from 5 others
$108,264in research payments, 2019–2025

Across 39 payments — averaging $2775.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$70K
  • Sun Pharmaceutical Industries Inc.$23K
  • Gilead$15K

What the payments were for

  • Consulting fees$40040%
  • Food & beverage$60360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,003 in reported general payments places this provider in the 35th percentile of 102 rheumatology providers in Arizona.

See all rheumatology providers in Arizona

Medicare billing

Part B allowed, 2024
$7,035
Medicare patients
42
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept11$80,228
Prednisone37$202

Paid to pharmacies, not to this prescriber.

Other rheumatology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →